Fusion Pharmaceuticals Inc. Common Shares
FUSN
FUSN was delisted on the 3rd of June, 2024.
29 hedge funds and large institutions have $304M invested in Fusion Pharmaceuticals Inc. Common Shares in 2020 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 8 reducing their positions, and 27 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
37% less capital invested
Capital invested by funds: $483M → $304M (-$179M)
38% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 8
43% less funds holding
Funds holding: 51 → 29 (-22)
81% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 27
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$2.6M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.17M |
| 3 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
+$543K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$316K |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$144K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$8.81M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$5.68M |
| 3 |
DM
Deerfield Management
New York
|
-$3.89M |
| 4 |
UBS AM
Chicago,
Illinois
|
-$3.11M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
-$3.11M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SCM
51
Sio Capital Management
New York
| – | -$52K | -3,000 | Closed |
|
|
PE
52
Point72 Europe
London,
United Kingdom
| – | -$35K | -2,000 | Closed |
|
53
Legal & General Group
London,
United Kingdom
| – | -$18K | -1,000 | Closed |
|
|
PAM
54
Panagora Asset Management
Boston,
Massachusetts
| – | -$17K | -1,000 | Closed |
|
|
PCM
55
Pinz Capital Management
New York
| – | -$12K | -700 | Closed |
|
|
RWB
56
RMR Wealth Builders
Montclair,
New Jersey
| – | -$4K | -250 | Closed |
|
FUSN Hedge Fund Activity: Q3 2020 in Review
29 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Fusion Pharmaceuticals Inc. Common Shares (FUSN) for Q3 2020, worth a combined $304M — down 37% from $483M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of FUSN and 5 opened new positions — a net loss of 22 holders — while 8 trimmed existing stakes and 5 added.
The largest buyer was Federated Hermes, adding an estimated $2.6M. The largest seller was Morgan Stanley, cutting an estimated $8.81M.
- 29 institutional investors held Fusion Pharmaceuticals Inc. Common Shares (FUSN) as of Q3 2020, down from 51 in Q2 2020.
- Funds reported $304M of Fusion Pharmaceuticals Inc. Common Shares stock for Q3 2020, down 37% quarter-over-quarter.
- 5 funds opened new Fusion Pharmaceuticals Inc. Common Shares positions in Q3 2020 and 27 closed out, a net change of -22 holders.
- The largest Fusion Pharmaceuticals Inc. Common Shares buyer in Q3 2020 was Federated Hermes, an estimated $2.6M added.
- The largest Fusion Pharmaceuticals Inc. Common Shares seller in Q3 2020 was Morgan Stanley, an estimated $8.81M sold.
Based on aggregated 13F filings for Q3 2020.